Adrenal Gland/Adrenocortical Basket Trials (Multiple Types)Biliary Tract/Gall Bladder/Cholangiocarcinoma (GI)Bladder/Urothelial (GU)Bone Metastases Brain and Central Nervous System (CNS)Breast Cervical (GYN)Colon/Rectal/Anal (GI)Endocrine Cancers Endocrine Neoplasia Esophageal (GI)Gastric/Stomach (GI)Gastrointestinal (GI) (Multiple Types)General Solid Tumors (Multiple Types)GenitoUrinary (GU) (Multiple Types)GEP-NET (NEC)GI Stromal Tumor (GIST)Gynecologic (GYN) (Multiple Types)Head and Neck Cancers Hematological Malignancies Hepatocellular/Liver (GI)Hodgkins Lymphoma Insulinoma Kidney/Renal Cell Carcinoma (GU)Leukemias Lung Lymphomas Melanoma/Skin Cancers Mesothelioma Multiple Myeloma NeuroBlastoma NeuroEndocrine (NEC) (Multiple Types)NeuroEndocrine Carcinoma (NEC)Orbital Neoplasms Osteosarcoma Ovarian Ovarian/Primary Peritoneal (GYN)Pancreatic (GI)Paraganglioma (NEC)Penile (GU)Pheochromocytoma (NEC)Pituitary Prostate (GU)Salivary Gland Sarcoma Synovial Carcinoma Testicular (GU)Thymoma Thyroid Unknown Primary Cancers Uterine (GYN)Vulvar (GYN)

Bringing Radioligand Therapy (RLT) Clinical Trials to Your Fingertips

Featured Sponsor

Learn More See Trial

Featured News In Theranostics

ITM and Debiopharm Announce First Patient Imaged in New Study Arm of Phase 1/2 Trial Evaluating ITM-94 as Diagnostic Agent for Clear Cell Renal Cell Carcinoma (ccRCC)

Mon Jun 23 2025

First patient imaged in Phase III AMPLIFY trial with 64Cu-SAR-bisPSMA PET/CT

Thu May 29 2025

Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma

Wed Apr 02 2025

SNMMI 2025: STARLiT: Stereotactic Body Radiotherapy and 177Lu PSMA-617 in Locally Advanced Prostate Cancer

Thu Jul 24 2025

Improving Access to Nuclear Medicine: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD

Mon Jun 30 2025

Groundbreaking Cancer Therapy Clinical Trial with U.S. Department of Energy’s Accelerator-Produced Actinium-225 Set to Begin this Summer

Wed Jun 18 2025

Alpha Fusion, Inc. and Curadh MTR, Inc. to Enter into Strategic Partnership to Advance Global Development of Astatine-211 Based Radiopharmaceuticals

Mon Jun 30 2025

All News

Why TheranosticTrials.org?

The leading global platform for radiopharmaceutical & molecular imaging clinical trials

Global Reach

We are uniquely positioned at the heart of Theranostics.

Increasing Awareness

We're dedicated to increasing awareness about Theranostics and it's potential.

Fostering Engagement

We encourage active participation in the Theranostics community.

Building Connections

We connect physicians, clinics, and patients with Theranostic opportunities.

Comprehensive Resources

Access a complete list of cancer Theranostic Trials and educational materials.

Advancing the Field

We collaborate with key opinion leaders to push Theranostics forward.

Our Ultimate Goal

Provide more hope to cancer patients everywhere!

Navigating Tips

Pick Your Path

Stats

Theranostic Trials Global Ecosystem

View All

Isotopes

View details about the isotopes used in the trials listed on our site!

Learn more

LUTETIUM-177

Radioisotope: Lu-177

Theranostic Role: Therapeutic Agent & SPECT Imaging

T1/2 (Half-Life): 6.7 Days

Decay Mode: BETA, GAMMA

Energy: Eβeta max 497 keV, Gamma 113-208 keV

Range: In Tissue: 0.25-2mm

Decay Daughters: Hf177

Status: FDA Approvals: PLUVICTO® (2022), LUTATHERA® (2017)

SAMARIUM-153

Radioisotope: Sm153

Theranostic Role: Therapeutic

T1/2 (Half-Life): 1.9 Days

Decay Mode: BETA, GAMMA

Energy: Beta: Max 808 keV Gamma: 103 keV (28%)

Range: 0.6 mm

Decay Daughters: Eu153 (Stable)

Status: FDA Approval: QUADRAMET® (1997)

TECHNETIUM-99m

Radioisotope: Tc-99m

Theranostic Role: SPECT Imaging

T1/2 (Half-Life): 6 Hours

Decay Mode: GAMMA

Energy: 140 keV (89.1%)

Range: N/A

Decay Daughters: Tc99

Status: FDA Approval: First in 1980’s

Distinguished Investigator

A Distinguished Investigator of Theranostics is a level of distinction conferred upon an individual physician who has demonstrated a mastery of conducting novel radioligand therapies and molecular imaging clinical trials.

Professor Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD, FMedSci

Professor Johann de Bono is Regius Professor of Cancer Research at The Institute of Cancer Research and honorary consultant in medical oncology at The Royal Marsden Hospital. He led on the development of abiraterone, cabazitaxel, enzalutamide, olaparib, lutetium PSMA and the molecular genomic stratification and germline sequencing of advanced prostate cancer. Professor de Bono leads the Drug Development Unit at the Royal Marsden which comprises >100 staff and conducts >50 Phase I clinical trials at any one time and runs a research laboratory. He has been involved in developing more than 200 new agents and is currently evaluating many new drugs in early clinical trials. He has published >600 papers and has mentored many PhD students.

RLT Components

RADIOLIGAND THERAPY (RLT) is a highly effective approach to very accurately locating cancer cells and effectively killing those same cells by delivery various radioisotopes to a specific target that is located on a type of cancer. Some of the Radioisotopes are diagnostic for locating cancers & some therapeutic to treat the cancers.

There are several Components to a RLT that are simply demonstrated in the truck diagram including:

Cancer Targets
Ligand (demonstrated as the Truck GPS set to find a specific Target)
Diagnostic Radioisotopes (demonstrated as light bulbs that light the cancer Targets on a PET scan)
Therapeutic Radioisotopes (demonstrated as bombs that kill cancer cells that express the target with either Alpha or Beta radiation)
Linker (demonstrated as the hitch keeping the Radioisotope attached to the Ligand)
Chelator (demonstrated as the Trailers which keeps the Radioisotope on Target).

To learn more about the specific components being studied today on clinical trials around the world check out the RLT COMPONENTSTab.

View RLT Components